ALK and neuroblastoma: The response of NB-1 xenografts to ceritinib was transient, and tumors resumed growth 2 weeks after the start of the treatment (Figure 3A and Figure 3—source data 1), suggesting that single-agent ALK inhibition may not be sufficient to achieve durable response in a subset of ALK-driven neuroblastoma tumors.